Allergy Therapeutics
BalancedAGY·XLON·🇬🇧 GB
50%buys·50%sells
8 transactions$0Total buys·0 buys
$0Total sells·0 sells
22 insiders
Last: Feb 25, 2026
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Feb 25, 26 | ZQ Capital Management Limited | Transfer | $1 | |
| Jan 27, 26 | Shaun Furlong | Grant | $3K | |
| Jan 27, 26 | Manuel Llobet | Grant | $7K | |
| Jan 14, 25 | ZQ Capital Management Limited | Subscription | $22.3M | |
| Jan 14, 25 | Southern Fox Investments Limited | Subscription | $11.2M | |
| Nov 7, 17 | Manuel Llobet | Grant | $82 | |
| Nov 7, 17 | Manuel Llobet | Grant | $823 |
Allergy Therapeutics (AGY) has recorded 8 insider transactions from 2 insiders. Total insider buying volume stands at $0, while total selling volume is $0. Insider activity shows a balanced mix of buying and selling.
Allergy Therapeutics (AGY) has recorded 8 insider operations, including 0 open-market purchases ($0), 0 sales ($0) and 8 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is balanced.
Recent activity is concentrated over 2 months in the last year.
Across all 7 recorded transactions, the breakdown by type is: grant (4, 57%), subscription (2, 29%), transfer (1, 14%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Allergy Therapeutics has recorded 8 insider operations in total, including 0 open-market purchases ($0), 0 sales ($0) and 8 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on February 25, 2026.
Insiders at Allergy Therapeutics show balanced activity with 50% purchases and 50% sales. Total buy volume is $0 versus $0 in sales.
InsiderLens tracks 2 insiders at Allergy Therapeutics (AGY). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for AGY is neutral, based on a 50% buy ratio across 0 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Allergy Therapeutics comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.